Journal of Oncology Pharmacy Practice

Article	Citations
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class	46
A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide	34
Cancer patient experience of telephone clinics implemented in light of COVID-19	28
Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial	22
ISOPP Standards for the Safe Handling of Cytotoxics	20
Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations	18
Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. The first case report of bystander effect on bone	18
International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care	16
Impact of clinical pharmacy in oncology and hematology centers: A systematic review	15
Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab	13
Ambulatory chemotherapy: Past, present, and future	13
Applications and challenges in therapeutic drug monitoring of cancer treatment: A review	13
Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer	12
Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program	12
Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review	11
A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy	11
The safe handling of chemotherapy drugs in low- and middle-income countries: An overview of practices	11
Sensitivity and specificity of drug interaction databases to detect interactions with recently approved oral antineoplastics	11
Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis	10
Occupational exposure assessment in professionals who manipulate and administer antineoplastic drugs in a university hospital in Southern Brazil	10
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma	10
Dermatological side effects of immunotherapy drugs and targeted cancer therapies: Importance of dermatology and oncology collaboration	10
Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?	10
Role of clinical pharmacist in the palliative care of adults and elderly patients with cancer: A scoping review	10
A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study	9

Ribociclib induced acute kidney injury: A case report	9
Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation	9
A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population	9
Comparison of four immunoassays to an HPLC method for the therapeutic drug monitoring of methotrexate: Influence of the hydroxylated metabolite levels and impact on clinical threshold	8
The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma	8
Bromocriptine for the treatment of postoperative cerebellar mutism syndrome in pediatric patients: Three case reports	8
Global changes to the chemotherapy service during the covid-19 pandemic	8
Veliparib for the treatment of solid malignancies	8
Non-pharmacological integrative therapies for chronic cancer pain	8
Barriers and facilitators for the safe handling of antineoplastic drugs	8
ISOPP 2023 – Abstract Book	8
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma	8
Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study	8
CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset	7
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma	7
Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report	7
Evaluation and clinical impact of a pharmacist-led, interdisciplinary service focusing on education, monitoring and toxicity management of immune checkpoint inhibitors	7
Protective effects of Panax ginseng against doxorubicin-induced cardiac toxicity in patients with non-metastatic breast cancer: A randomized, double-blind, placebo-controlled clinical trial	7
Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin’s lymphoma	7
Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners	7
Severe cisplatin-induced renal toxicity in a patient with xeroderma pigmentosum	7
A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma	7
Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities?	7
Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges	7
Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City	7
Blood contamination of the pharmaceutical staff by irinotecan and its two major metabolites inside and outside a compounding unit	7
Dosing of PD-1 and PD-L1 inhibitors: Cost saving initiatives for significantly decreasing associated expenditure	6
The drugs screened by OncoVeeTM-Mini-PDX have significantly benefited the patient with HER2-positive advanced gastric cancer	6
Fluconazole-Induced adrenal insufficiency following allogeneic hematopoietic cell transplant	6
Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?	6
Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting	6
Evaluation of external contamination on the vial surfaces of some hazardous drugs that commonly used in Chinese hospitals and comparison between environmental contamination generated during robotic co	6
Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma	6
Adherence to thalidomide in patients with multiple myeloma: A cross-sectional study in a Brazilian metropolis	6
Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia	6
Two different immune related adverse events occured at pancreas after nivolumab in an advanced RCC patient	6
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia	6
Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review	6
Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant	6
The burden of polypharmacy and drug–drug interactions in older cancer patients treated with immunotherapy	6
Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 151	6
Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)	6
Perception, knowledge, and handling practice regarding the risk of exposure to antineoplastic drugs in oncology day hospitalization units and compounding unit staff	6
Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma	6
Increasing pharmacy productivity and reducing medication turnaround times in an Italian comprehensive cancer center by implementing robotic chemotherapy drugs compounding	6
A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer	6
Impact of oncology pharmacist services on humanistic outcome in patients with breast cancer	6
The efficacy and safety of alpelisib in breast cancer: A real-world analysis	6
Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion	6
Hypercalcemia associated with the interaction between all trans retinoic acid and posaconazole in an acute promyelocytic leukemia case	6

Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting	6
Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization	6
Updates in the use of targeted therapies for the treatment of cholangiocarcinoma	6
Evaluation of a patient self-medication program in allogeneic hematopoietic stem cell transplantation	6
Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic, programmed death-ligand 1-positive, non-small-cell lung cancer	6
Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma	6
Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients	6
Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies	6
Novel agents for myelodysplastic syndromes	5
Preservation of cognitive function after brain irradiation	5
Unmet supportive care needs and predictor of breast cancer patients in Bangladesh: A cross-sectional study	5
Trousseau’s syndrome in a non-small cell lung cancer patient aggravated by pembrolizumab	5
Papilledema and idiopathic intracranial hypertension due to the possible potentiation of ATRA by posaconazole in a case of acute promyelocytic leukemia	5
Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions	5
Unmet supportive care needs and determinants among cancer patients treated at University of Gondar Specialized Hospital, Northwest Ethiopia: A prospective cross-sectional study	5
Capecitabine induced Steven–Johnson syndrome: A rare case report	5
The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials	5
Aplastic anemia secondary to tyrosine kinase inhibitor therapy in a patient with chronic myeloid leukemia	5
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis	5
Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury	5
Updates on the molecular mechanisms of aspirin in the prevention of colorectal cancer: Review	5
Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature	5
A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenström’s macroglobulinemia	5
Drug extravasation with Enfortumab vedotin	5
Impact of anti-cancer drugs shortages in oncology and hematology departments in a Moroccan hospital	5
Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer	5
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach	5
An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)	5
Case of metastatic kaposi sarcoma successfully treated with anti-PD-1 immunotherapy	5
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation	5
Patterns of complementary and alternative medicine use among Tunisian cancer patients	5
Sustained erythrocytosis due to the use of Lenvatinib	5
Real-world effectiveness of the pegfilgrastim on-body injector in preventing severe neutropenia	5
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia	5
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer	5
Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards	5
Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors	5
Retrospective analysis of the incidence and severity of acute kidney injury (AKI) in patients with head and neck cancer receiving weekly cisplatin with radiotherapy (RAISe-AKI)	5
Immunosuppression medication adherence after allogeneic hematopoietic stem cell transplant: Impact of a specialized clinical pharmacy program	5
Perspectives toward biosimilars among oncologists: A Malaysian survey	5
PAX2 promoter methylation and AIB1 overexpression promote tamoxifen resistance in breast carcinoma patients	5
Abstracts	5
Implementation of a clinical pharmacist-led service to optimize management of refractory chemotherapy-induced nausea and vomiting in adult hematology/oncology clinic	5
Addressing the Challenges of Novel Oncology and Hematology Treatments Across Sites of Care: Specialty Pharmacy Solutions	4
Pericardial effusion with pembrolizumab	4
Comparison of different decision support software programs in perspective of potential drug–drug interactions in the oncology clinic	4
Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy	4
Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia	4
Vascular endothelial growth factor inhibitor induced hypertension: Retrospective analysis of the impact of blood pressure elevations on outcomes	4
Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?	4
Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab	4
Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib	4
Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations	4
Accurate determination of glomerular filtration rate in adults for carboplatin dosing: Moving beyond Cockcroft and Gault	4
The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs	4
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer	4
Gemcitabine-induced dilated-cardiomyopathy in patient with platinum-refractory ovarian-cancer: A case report and literature review	4
Does nutritional status affect treatment tolerability, chemotherapy response and survival in metastatic gastric cancer patients? Results of a prospective multicenter study in Turkey	4
Drug- and patient-related factors are the strongest predictors of endocrine therapy adherence in breast cancer patients	4
Late side effects of cancer treatment in childhood cancer survivors	4
Results of a pre-implementation analysis of Ethiopia’s National Pediatric Cancer Registry	4
Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers	4
Implementation and outcomes of a pharmacist-led oral chemotherapy clinic at VA Maine Healthcare System	4
Oncologists’ attitudes towards prophylaxis of cancer associated venous thromboembolism: A prospective, descriptive study	4
A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”	4
How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs	4
Nivolumab–ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment	4
Progressive Multifocal Leukoencephalopathy Among Ibrutinib Treatment In Chronic Lymphocytic Leukemia	4
Oral cancer awareness and education within the pharmacy profession	4
Chemotherapy-induced neutropenia among breast Cancer patients in a tertiary care hospital: Risk and consequences	4
Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor	4
Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre	4
Osteonecrosis of the jaw under palbociclib: A case series description	4
Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method	4
Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units	4
Citrobacter braakii CLABSI in a hematopoietic stem cell transplant patient	4
HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma	4
Extemporaneous compounding and administration of tretinoin slurry for acute promyelocytic leukemia	4
Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature	4
Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma	4

Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer	4
Possible heart failure caused by osimertinib in a lung cancer patient	4
Evaluation of early de-escalation of empiric antimicrobial therapy in acute leukemia patients with febrile neutropenia at a large academic medical center	4
The design, implementation and evaluation of hybrid cancer clinic simulations: Escaping the norm	4
Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial	4
Trastuzumab and pertuzumab in hemodialysis: A case report	4
Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival?	4
Reduced emergency room visits and improved medication adherence of an integrated oncology pharmaceutical care practice in China	4
Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy	4
Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists	4
Current practices, gaps, and opportunities on the role of clinical pharmacists in cancer pain management: Perspectives from Nepal	4
Vitamin E and levocarnitine as prophylaxis against doxorubicin-induced cardio toxicity in the adult cancer patient: A review	4
Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report	4
Innovative strategies for effective paclitaxel delivery: Recent developments and prospects	4
Contribution of an anticancer drug compounding robot in reducing the risks of manual preparation in a hospital pharmacy unit specialized in oncology	4
Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy	4
Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report	4
Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metab	4
Economic impact of implementation of an automated drug supplying and management system in a Central Chemotherapy Preparation Unit in a Moroccan hospital	4
Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series	4
Alternate dosage formulations of oral targeted anticancer agents	4
Robotic chemotherapy compounding: A multicenter productivity approach	4
Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists	3
Clinical and Economic Impact of Pharmacists’ Intervention on Care of Pediatric Hematology and Oncology Patients	3
Retrospective review of accelerated daratumumab administration	3
Patient-reported outcomes and digital literacy of patients treated in an oncology day hospital unit	3
Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center	3
Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab	3
Venetoclax ramp-up with concurrent voriconazole in a patient with chronic lymphocytic leukemia	3
Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma	3
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma	3
Impact of the implementation of a pharmacist-driven immunosuppression drug monitoring protocol for hematopoietic stem cell transplant recipients	3
Bendamustine-induced nephrogenic diabetes insipidus – A case report	3
Changing therapeutic landscape in advanced Kaposi sarcoma: Current state and future directions	3
The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma	3
Ado-trastuzumab emtansine associated spider telangiectasia	3
Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness	3
Unexpected pancytopenia: Dasatinib induced aplastic anemia in chronic myeloid leukemia	3
Comment on Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions	3
Use of long-term corticosteroids in patients treated with CAR T-cell therapy	3
Exploring practice site contributions and professionalization impact of engaging student pharmacists on hematology-oncology advanced pharmacy practice experience rotations	3
Abiraterone acetate-associated QT prolongation and torsades de pointes: Postmarketing cases reported to FDA	3
Autoimmune hemolytic anemia in a patient with myelodysplastic syndrome: Responding to 5-azacitidine therapy	3
Preventing drug vial wastage and reducing expenditure associated with injectable cancer drugs: International oncology pharmacy survey	3
Alectinib-induced hemolytic anemia	3
Trastuzumab-emtansine induced pleural and pericardial effusions	3
Design and stability of pediatric oral formulation of imatinib	3
Tolerability of palbociclib in younger and older patients with advanced breast cancer	3
Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey	3
Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer	3
Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma	3
Pharmacists’ interventions on 2 years of drug monitoring in an oncology pediatric inpatient ward	3
A study to assess the impact of pharmaceutical care services to cancer patients in a tertiary care hospital	3
Delayed hypersensitivity to oxaliplatin in a nigerian patient with colorectal cancer—A case report	3
Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review	3
Life-threatening altered mental status secondary to memantine in an adolescent undergoing cranial radiotherapy for medulloblastoma	3
Anti-cancer medicine shortages in an oncology tertiary hospital of Pakistan: A five-year retrospective study	3
Motor “freezing” with oxaliplatin	3
A pilot study about methods to reduce prescription errors in a chemotherapy day unit – Aspects to consider in pharmacist verification process	3
Capecitabine induced fingerprint loss: Case report and review of the literature	3
Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia	3
Expanding oncology pharmacist teams: Justifying the return on investment	3
Development of a process map for the delivery of virtual clinical pharmacy services at Odette Cancer Centre during the COVID-19 pandemic	3
A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®)	3
Antineoplastic extravasation management: Consensus of the Spanish Oncology Pharmacy Group (GEDEFO)	3
Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation	3
Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity	3
Cutaneous Stevens Johnson – Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients	3
Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma	3
Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study	3
A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions	3
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities	3
Health care seeking behaviors and perspective on indigenous palliative care among cancer patients in Kenya	3
Vortex keratopathy associated with ribociclib	3
Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases	3
Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R	3
A prospective study to evaluate the efficacy and safety of vitamin E and levocarnitine prophylaxis against doxorubicin-induced cardiotoxicity in adult breast cancer patients	3
Cost analysis of daratumumab therapy: Is there a cost benefit to using the recently approved subcutaneous product versus the IV product?	3
BOPA 2022 – Abstract Book	3
Risks of hepatitis C virus reactivation in a real-life population of oncology patients treated in an academic center	3
Oncology boot camp: A preparatory curriculum for advanced pharmacy practice experience students	3
Dangerous interaction of bitter melon (Momordica charantia) with pazopanib: A case of acute pancreatitis	3
Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome	3
Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients	3
Pharmacokinetic characterization, benefits and barriers of subcutaneous administration of monoclonal antibodies in oncology	3
Evaluation of voriconazole related adverse events in pediatric patients with hematological malignancies	3
Not only a time-saving approach: Is it the time of subcutaneous formulation for daratumumab administration?	3
Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting	3
Updates in the management and future landscape of urothelial carcinoma	3
Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective	3
Knowledge assessment and barriers to cancer screening among Ghanaian community pharmacists	3
Acceptance of coronavirus disease 2019 vaccination by cancer patients in Cyprus: A cross-sectional study	3
Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients	3
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?	3
Rapid rituximab infusion is safe and well tolerated in malignant and benign disease	3